Naproxen

證據等級: L5

預測適應症: 4 個

Naproxen: From NSAID Therapy (Original Indication Not on Record) to Brachydactyly-Syndactyly Syndrome

One-Sentence Summary

Naproxen is a long-established NSAID (COX-1/COX-2 inhibitor), though this evidence pack contains no recorded original indication or Taiwan/US license data for it. The TxGNN model predicts possible efficacy for Brachydactyly-Syndactyly Syndrome, a rare congenital limb malformation syndrome, but 0 clinical trials and 0 publications currently support this direction, and the model’s own rationale notes no known biological link.

Quick Overview

Item	Content
Original Indication	Not available — no license records or original indication data in this evidence pack
Predicted New Indication	Brachydactyly-Syndactyly Syndrome
TxGNN Prediction Score	99.35% (rank 14,678 among candidates)
Evidence Level	L5 (model prediction only, no supporting trials or literature)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism-of-action data for naproxen is flagged as a data gap in this evidence pack (High severity — DG002). However, the model’s own repurposing rationale references naproxen’s well-known pharmacology as a COX-1/COX-2 inhibitor that suppresses prostaglandin synthesis — the standard NSAID mechanism.

Brachydactyly-syndactyly syndrome is a rare congenital skeletal/limb malformation syndrome rooted in embryonic limb-patterning gene regulation, not in inflammation or prostaglandin-mediated pathology. The evidence pack’s own rationale states explicitly that there is no known mechanistic link between COX-1/COX-2 inhibition and this disorder’s developmental pathology, and that the high TxGNN score (0.9935) reflects knowledge-graph node-embedding similarity rather than any biological hypothesis.

The same pattern holds across the other top-ranked candidates in this pack (colobomatous microphthalmia-rhizomelic dysplasia syndrome, acromesomelic dysplasia Hunter-Thompson type, brachyolmia-amelogenesis imperfecta syndrome) — all are rare monogenic skeletal/structural developmental disorders with rationale text stating no known mechanistic connection to naproxen. This consistency across the top 4 predictions suggests the model signal here is not anchored to plausible biology for this drug.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Naproxen has 0 recorded licenses in this evidence pack, and market status is listed as Not Marketed. No authorization records are available to summarize.

Safety Considerations

Please refer to the package insert for safety information. (TFDA label/warning data is a Blocking-severity gap in this evidence pack — DG001 — and must be resolved before any safety review can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is an ultra-rare congenital skeletal syndrome with L5 evidence (model score only — zero trials, zero literature) and an explicit statement in the rationale that no biological mechanism connects naproxen’s COX-1/COX-2 inhibition to this disorder. Combined with the absence of Taiwan/US market presence and unresolved MOA/label data gaps, this candidate does not meet the threshold to advance.

To proceed, the following is needed:

TFDA label (warnings/contraindications) — currently a Blocking gap
Confirmed MOA data via DrugBank API — currently a High-severity gap
A biological or preclinical rationale linking NSAID/COX pathways to limb-patterning or skeletal dysplasia pathogenesis, which does not currently exist for this candidate
Re-evaluation against lower-ranked, mechanistically plausible predicted indications if this pipeline continues for naproxen
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.